-+ 0.00%
-+ 0.00%
-+ 0.00%

Tango Therapeutics names Matthew Gall CFO, replacing Daniella Beckman

PUBT·04/15/2026 13:06:57
Listen to the news
Tango Therapeutics names Matthew Gall CFO, replacing Daniella Beckman
  • Tango Therapeutics appointed Matthew Gall as chief financial officer effective April 15, replacing Daniella Beckman.
  • Gall previously served as CFO at Kalaris Therapeutics, CFO at iTeos Therapeutics, held finance, business development, corporate strategy roles at Sarepta Therapeutics, Celgene, Gilead Sciences.
  • Yen-Ching Chua named chief development operations officer effective June 1 to oversee clinical operations, data management, quality, clinical compliance, clinical sourcing.
  • Chua previously led clinical and development operations at Novocure, Debiopharm International, MorphoSys, Novartis.
  • Janice Kapty appointed SVP, corporate strategy and project leadership effective April 15, with prior drug development leadership roles at Arvinas, MorphoSys, Constellation Pharmaceuticals, Bristol Myers Squibb, Celgene.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150905PRIMZONEFULLFEED9690073) on April 15, 2026, and is solely responsible for the information contained therein.